Evidence map›Paper›PMID 40796376›Full record

ArticleGigaScience2025

SynProtX: a large-scale proteomics-based deep learning model for predicting synergistic anticancer drug combinations.

Bundit Boonyarit, Matin Kositchutima, Tisorn Na Phattalung, Nattawin Yamprasert, Chanitra Thuwajit, Thanyada Rungrotmongkol, Sarana Nutanong

Abstract read
In one paragraph

Article in GigaScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bundit BoonyaritSchool of Information Science and Technology, Vidyasirimedhi Institute of Science and Technology, Rayong 21210, Thailand.ORCID 0000-0003-4425-2608
Matin KositchutimaKamnoetvidya Science Academy, Rayong 21210, Thailand.ORCID 0009-0004-1215-4397
Tisorn Na PhattalungKamnoetvidya Science Academy, Rayong 21210, Thailand.ORCID 0009-0006-5835-6351
Nattawin YamprasertSchool of Information, Computer, and Communication Technology, Sirindhorn International Institute of Technology, Thammasat University, Pathum Thani 12120, Thailand.ORCID 0009-0004-3302-0734
Chanitra ThuwajitDepartment of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.ORCID 0000-0001-9506-6405
Thanyada RungrotmongkolProgram in Bioinformatics and Computational Biology, Graduate School, Chulalongkorn University, Bangkok 10330, Thailand.ORCID 0000-0002-7402-3235
Sarana NutanongSchool of Information Science and Technology, Vidyasirimedhi Institute of Science and Technology, Rayong 21210, Thailand.ORCID 0000-0003-1068-850X

Funding

Vidyasirimedhi Institute of Science and Technology
6 · The paper itself

Abstract

motivationDrug combination therapy plays a pivotal role in addressing the molecular heterogeneity of cancer, improving treatment efficacy, minimizing resistance, and reducing toxicity. Deep learning approaches have significantly advanced drug combination discovery by addressing the limitations of conventional laboratory experiments, which are time-consuming and costly. While most existing models rely on the molecular structure of drugs and gene expression data, incorporating protein-level expression provides a more accurate representation of cellular behavior and drug responses. In this study, we introduce SynProtX, an enhanced deep learning model that explicitly integrates large-scale proteomics with deep neural networks (DNNs) and the molecular structure of drugs with graph neural networks (GNNs).

resultsThe SynProtX-GATFP model, which combines molecular graphs and fingerprints through a graph attention network architecture, demonstrated superior predictive performance for the FRIEDMAN study dataset. We further evaluated its cell line-specific performance, which achieved accuracy across diverse tissue and study datasets. By incorporating protein expression data, the model consistently enhanced predictive performance over gene expression-only models, reflecting the functional state of cancer cells. The generalizability of SynProtX was rigorously validated using cold-start prediction, including leave-drug-combination-out, leave-drug-out, and leave-cell-line-out validation strategies, highlighting its robust performance and potential for clinical applicability. Additionally, SynProtX identified key cancer-associated proteins and molecular substructures, offering novel insights into the biological mechanisms underlying drug synergy. These findings highlight the potential of integrating large-scale proteomics and multiomics data to advance anticancer drug design and combination therapy strategies for personalized medicine. Availability and implementation:  https://github.com/manbaritone/SynProtX.

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsDeep LearningNeoplasmsProteomicsCell Line, TumorDrug SynergismHumansNeural Networks, ComputerAntineoplastic Agentscancer drug combinationdeep learningdrug discoverygraph neural networksmachine learningmultiomicspersonalized medicineproteomicssynergistic effect

Identifiers

PMID40796376
PMCPMC12343095

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.